

**BTS recommendations for assessing risk, and for managing
M.tuberculosis infection and disease in patients due to start
anti-TNF-alpha treatment**

British Thoracic Society Standards of Care Committee

Subcommittee - L.P.Ormerod (Chair), H.J.Milburn, S.Gillespie ;
J.M.Ledingham ; D.S.Rampton

**FINAL VERSION
SOCC APPROVED**

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in Thorax editions and any other BMJPG products to exploit all subsidiary rights, as set out in our licence (<http://thorax.bmjournals.com/misc/fora/licenceform.shtml>).

Membership

Professor Peter Ormerod, Consultant Chest Physician Blackburn Royal Infirmary, Blackburn, Lancs BB2 3LR, UK.

Dr Heather Milburn, Consultant Chest Physician, Guys and St Thomas Hospitals, London SE1 9RT.

Professor Stephen Gillespie, Consultant Microbiologist, Dept of Medical Microbiology, Royal Free and University College Medical, London NW3 2PF.

Co-opted:-

Dr Jo Ledingham, Consultant Rheumatologist, Queen Alexandra Hospital Portsmouth PO6 3LY (representing the British Society of Rheumatology).

Professor David Rampton, Consultant Gastroenterologist, Barts and the London NHS Trust, London E1 1BB (representing the British Society of Gastroenterology).

Introduction

In view of the increased risk of TB reactivation with anti-TNF alpha treatment, various professional groups have sought the advice of the Joint Tuberculosis Committee of the British Thoracic Society. The objectives of these guidelines are to quantify these risks, and to give advice on the treatment of TB disease and infection, in patients being assessed for anti-TNF alpha treatment. The risks and benefits of treatment for latent TB infection, in those unsuitable for tuberculin skin testing, are also covered. These guidelines are intended to inform respiratory physicians, gastroenterologists, rheumatologists and dermatologists, together with specialist nurses in those disciplines.

Abstracted bullet points

- * In patients receiving anti-TNF-alpha treatment there is an increased risk of clinical tuberculosis (TB) developing.
- * Patients should have a clinical examination, their history of any prior TB treatment checked, a chest X-ray and if appropriate a tuberculin test (see text). Any patient with an abnormal chest X-ray or previous history of TB or TB treatment should be referred for assessment by a specialist with an interest in TB.(D)
- * Patients with an abnormal chest X-ray and/or symptoms raising a suspicion of TB should be thoroughly investigated to exclude active disease. (D)
- * Any patient with active TB, either pulmonary or non-pulmonary, should receive standard chemotherapy (A).
- * Patients with active TB should receive a minimum of 2 months full chemotherapy directed by a specialist in TB, before starting anti-TNF-alpha treatment. (D)
- * Patients with an abnormal chest X-ray consistent with past TB, or a history of

4.

prior extra-pulmonary TB but who have received previous adequate treatment, should be monitored regularly.(D)

- * Active TB should be excluded by appropriate investigations in patients with an abnormal chest X-ray or a history of prior pulmonary or extra-pulmonary TB not previously adequately treated, should have active TB excluded. Chemoprophylaxis should be given before commencing anti-TNF-alpha treatment. (A)
- * For patients with a normal chest X-ray who are not on immunosuppressive therapy a tuberculin test is helpful in management: an algorithm is supplied. (D)
- * For those with a normal chest X-ray who are on immunosuppressive therapy a tuberculin test will not be helpful and need not be undertaken. An individual risk-assessment should be made (Tables 3-4); if the annual risk of TB is greater than the risk of drug-induced hepatitis, then chemoprophylaxis should be given (C). If the risk of hepatitis is the greater the patient should be monitored regularly with suggestive symptoms promptly investigated to permit early diagnosis of active disease. An algorithm is supplied (C). In general, Black-African patients aged over 15, and all South Asians born outside the UK, should be considered for chemoprophylaxis with isoniazid for 6 months (6H).
- * Close co-operation between clinicians prescribing anti-TNF therapy and specialists in the management of TB is strongly recommended.(D)

ALGORITHM FOR MANAGEMENT OF TB IN PATIENTS SCHEDULED FOR anti-TNF-alpha TREATMENT

Notes for algorithm

Mantoux equivalence for Heaf tests will be 0-5mm induration = Heaf grade 0-1: 6-14mm Heaf 2: 15mm or greater Heaf 3-4

Where the Tuberculin test is unreliable this should not be performed and patients stratified for TB risk (see Tables 3-4)

Give chemoprophylaxis if TB risk (Tables 3-4) greater than chemoprophylaxis (Table 5). In general, Black-African aged over 15, and all South-Asians born outside the UK should be considered for chemoprophylaxis with isoniazid for 6 months (6H).

If chemoprophylaxis risk is greater than TB risk repeat chest X-ray within 3 months of starting anti-TNF treatment/investigate if required.

All patients on TB treatment or prophylaxis should have this managed by thoracic or infectious disease physician. Clinical awareness of the possibility of TB should be maintained throughout anti-TNF treatment and for a period of up to 6 months after cessation of anti-TNF treatment.

1. Search methodology

1.1. Structure of the recommendations

The format follows that used for other BTS guidelines. At the start there is a summary of the abstracted bullet points from each section. Following that there is an algorithm summarizing the management of patients due to start anti-TNF-alpha treatment. The recommendations use the revised SIGN grading system available on <http://www.sign.ac.uk/guidelines/fulltext/50/section6.html> (Table 1). The primary source literature has been individually graded for its methodology (where appropriate) and the grading is given alongside the reference using the revised SIGN levels of evidence (Table 2).

1.2. Methodology for the generation of the recommendations

The initial systematic literature search (Pubmed, EMBASE) was carried out by one of the committee (LPO), using tuberculosis and biologics 1997-2003 and chemoprophylaxis for TB and hepatitis 1966-2002 as search criteria. A paper-based exploration of the relevant literature was pursued from this core dataset.

Only English language literature, including clinical trials and all well-formulated clinical case series were identified. Isolated case reports and abstracts were excluded.

After the data appraisal, the guideline was initially drafted by LPO, and then discussed by the whole group, the evidence debated, and several re-draftings took place. The draft was based where possible on the published evidence, but this was combined with clinical expertise where required. The resulting draft was a blend

7

of published evidence and clinical expertise. The manuscript was then placed on the BTS website for consultation by the membership, it was also reviewed by the British Societies for Rheumatology and Gastroenterology. Following this, further amendments took place, and the document was reviewed by the Joint Tuberculosis and Standards of Care Committees of the BTS. After final approval from this Committee, the Guidelines were submitted for peer review prior to publication

1.3 Conflict of interest

All members of the Guideline Committee were asked to submit a written record of possible conflicts of interest to the Standards of Care Committee of the BTS.

None were recorded

2. Introduction

2.1 The need for recommendations

The increase in active tuberculosis associated with anti-TNF therapy^{1,9-11} has led to a requirement to screen for active and latent tuberculosis in patients before anti-TNF-alpha treatment is given. This screening, suggested by manufacturers to include tuberculin skin testing, is further complicated by the fact that many patients, up to 79% in the infliximab study¹, were receiving immunosuppressive therapy such as maintenance prednisolone, azathioprine, 6-mercaptopurine, methotrexate, cyclophosphamide, ciclosporine, tacrolimus or mycophenolate mofetil which would interfere with the accuracy of tuberculin skin testing^{2,3}. The product licence for infliximab states that the product should be used in conjunction with methotrexate or other immunosuppressants, and in practice the other anti-TNF agents would also normally be used with other immunosuppressants. Chemoprophylaxis, or preventive therapy, for TB itself carries a small risk, with drug induced hepatitis being the main issue, increasing

with age and occasionally fatal. It is also important to exclude active TB disease before chemoprophylaxis is given, particularly as single agent chemoprophylaxis given when active disease is present could lead to the development of drug resistance. These problems have led to many requests for advice in this area.

2.2 Background Epidemiology

Infliximab, a murine human chimeral monoclonal antibody against TNF-alpha, is approved in the USA and Europe for the treatment of rheumatoid arthritis⁴ and

9

Crohn's disease⁵ and ankylosing spondylitis. Etanercept is a fusion protein that binds free TNF-alpha using the soluble portion of tumour necrosis factor receptor (TNFR2) coupled with an Fc moiety⁶, and is also used in the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthropathy and juvenile idiopathic arthritis. Adalimumab, a recombinant fully humanized monoclonal antibody against TNF, became licensed for the treatment of rheumatoid arthritis in September 2003⁷.

Post-marketing surveillance in the USA and beyond to the end of May 2001, showed 70 cases of TB associated with infliximab use¹, a much lower number of cases being reported with etanercept¹. Cases of TB are also described with Adalimumab⁸. The majority of the cases of TB in patients given infliximab occurred within 3 cycles of treatment, with a median of 12 weeks after commencing treatment⁷. The frequency of tuberculosis was much higher than other opportunist infections reported with the drug, and was higher than reported background rates⁹. Over 50% of reported TB cases associated with anti-TNF alpha therapy are extra-pulmonary⁹. The number of cases of TB reported to the US Food and Drugs Administration had risen to 117 by December 2001, giving re-calculated TB prevalence of 41/100000 in infliximab/etanercept treated USA patients with rheumatoid arthritis, 9/100000 in USA patients with Crohn's disease, and 224/100000 in all non-USA patients with rheumatoid arthritis or Crohn's disease¹⁰. The number of TB cases now reported has reached 242 (Keane J personal communication 2004), the curve of which has leveled off due to either

improved TB risk assessment, tuberculin testing and isoniazid prophylaxis, and/or reporting fatigue.

The estimated prevalence of tuberculosis in rheumatoid arthritis patients in the USA is 6.2/100000 (95% CI 1.6-34)¹¹, with that in patients on infliximab being originally 24.4/100000¹, an approximate four-fold increase.. In a second part of the prevalence study¹¹, TB incidence among infliximab-treated patients was 52.5/100000 (95% CI 14.3-134.4), an approximate 8-fold increase, but based on only a very small number of TB cases. Overall the subcommittee believes the average risk factor for anti-TNF-alpha treatment to be a five-fold increase {D}.

[3] Risks of tuberculosis and of drug-induced hepatitis from chemoprophylaxis

3.1 Risks of tuberculosis

Tuberculosis incidence varies markedly within the United Kingdom (UK) according to a number of factors^{12,13}. These are age, ethnic group, and for those non-UK born, the length of time since first entry. Where possible data on the current annual risk of tuberculosis have been updated from those derived from continuous enhanced surveillance (Table 3).

3.2 Risks of drug-induced hepatitis from TB chemoprophylaxis

A database search (Medline and Embase) was carried out on the reported hepatotoxicity of antituberculosis chemoprophylaxis from 1966-2002 in adults. Children were excluded because they have a very low rate of drug reactions, and studies in HIV-positive individuals excluded because such individuals have a higher than normal drug reaction profile¹⁴. The hepatitis rates for various regimens were derived from these data (Table 5).

Only hepatitis sufficient to stop treatment (symptomatic) or Grade 3 alanine transferase (ALT 5-20 times normal) or grade 4 (ALT > 20 times normal) hepatitis is reported here. Co-infection with HIV, hepatitis B or C contraindicate the use of anti-TNF therapies according to manufacturers, so this guidance does not apply to patients with these co-infections.

4. Recommendations

4.1 Assessment before anti-TNF treatment

Patients should have a clinical examination, their history of any prior TB treatment checked, a chest X-ray and if appropriate a tuberculin test (Sections 4.4 and 4.5). Any patient with an abnormal chest X-ray or previous history of TB or TB treatment should be referred to a specialist with an interest in TB, either a thoracic or infectious disease physician. Close co-operation between clinicians prescribing anti-TNF therapy and specialists in the management of TB is strongly recommended. (D)

4.2 Active TB found before anti-TNF alpha treatment

Patients with chest X-ray abnormalities (e.g. infiltrates, cavitation, pleural effusion or mediastinal lymphadenopathy) and/or symptoms raising a suspicion of tuberculosis should be thoroughly investigated to exclude active disease. This should include sputum microscopy and culture for acid-fast bacilli, and if indicated bronchoscopy and washings, and biopsy and culture of pleura and/or

mediastinum. Extra-pulmonary sites may require material to be obtained by aspiration for culture or biopsy for culture and histology. (D)

Any person with active TB, either pulmonary or non-pulmonary, should receive standard chemotherapy¹⁵ (A). Anti-TNF-alpha treatment should not be commenced a) for at least two months after antituberculosis treatment with full compliance has begun, supervised by a thoracic physician or infectious disease specialist, and b) until the drug susceptibility profile of the organism in

13

those with positive cultures is known, as a minimum.(D) Ideally it would be preferable to delay anti-TNF treatment until completion of a full course of anti-tuberculosis treatment. (D)

4.3 Inactive tuberculosis found before anti-TNF-alpha treatment

a) Previous adequate treatment

Patients with an abnormal chest X-ray consistent with past tuberculosis, or a history of prior extra-pulmonary TB but who have received previous adequate

treatment, as judged by a thoracic or infectious disease physician, can start anti-TNF-alpha treatment but should be monitored clinically every 3 months, with a chest X-ray and sputum cultures if respiratory symptoms develop. (D) The onset of new respiratory symptoms, particularly within 3 months of commencing anti-TNF treatment, should be investigated promptly (D).

b) Previous inadequate treatment

Patients with an abnormal chest X-ray or a history of prior pulmonary or extra-pulmonary TB not previously adequately treated, should have active tuberculosis excluded by appropriate investigations (see 4.2) under the care of a thoracic or infectious disease physician. In such individuals even when active disease has been excluded, the annual risk of tuberculosis (reactivation) is much higher than the general population rate¹⁶, so the risk-benefit analysis strongly favours chemoprophylaxis (section 4.6)(A).

Ideally, chemoprophylaxis for TB for patients in this category should be completed before starting anti-TNF treatment. If the clinician is concerned

about the potential 6 month delay in starting such treatment, discussion should be held with the patient and the clinician supervising chemoprophylaxis, about using a shorter (but potentially more toxic) chemoprophylaxis regimen (see 4.6).(D)

4.4 Patients with normal chest X-rays and assessable by skin tuberculin test

For patients with a normal chest X-ray who are not on immunosuppressive therapy, a tuberculin test is helpful in management. The tuberculin test needs to be interpreted in the light of the BCG history. In those without a BCG history, Heaf grades 0-1 (Mantoux 1:10000 0-5mm) are negative, but Heaf grades 2-4 (Mantoux 1:10000 6mm or greater) are positive, and should lead to a risk assessment. In those with a prior BCG history, confirmed by scar or adequate documentation, Heaf 0-2 grades (Mantoux 1:10000 0-14mm) need no action, but Heaf grades 3-4 (Mantoux 1:10000 15mm or greater) may represent either latent infection or BCG effect, so require a risk assessment: an algorithm is supplied (Figure 1). (C)

4.5 Patients with normal chest X-rays and not assessable by skin tuberculin test

The majority of potential recipients of anti-TNF-alpha medication will have a normal chest X-ray and will have been on immunosuppressive therapy thus hindering the interpretation of tuberculin testing³. In these individuals an individual risk-benefit calculation will be needed. The estimated annual risk of tuberculosis disease (Table 3) should be multiplied by a factor of 5 to give an annual risk on anti-TNF treatment^{1,11}, based on the current reported rates of TB in

15

association with such therapies (D).

If the calculated annual risk on anti-TNF treatment is higher than the risk of hepatitis, then the risk/benefit favours chemoprophylaxis; if lower the risk/benefit calculation favours observation and investigation of symptoms. Table 4 gives worked examples(C). In general, Black-Africans aged over 15, and all South Asians born outside the UK should be considered for chemoprophylaxis with isoniazid for 6 months (6H).

4.6 Chemoprophylaxis

There are 2 potential chemoprophylaxis regimens: isoniazid for 6 months (6H), rifampicin plus isoniazid for 3 months (3RH). Rifampicin and pyrazinamide for 2 months (2RZ) was a regimen used in the USA¹⁷, but had a very high hepatitis rate (Table 5) with a number of fatalities reported^{18,19}. Accordingly the choice of regimen is between 6H which has a lower hepatitis rate, and 3RH which may have advantages in terms of shorter duration and thus possibly better adherence (Table 5), and also less risk of drug resistance developing if active disease is present (A). The decision on the chemoprophylaxis regimen should be made by the thoracic or infectious disease physician following informed discussion with both the patient and the referring clinician. (D)

In contrast to patients falling into category 4.3b (above), chemoprophylaxis for patients with normal chest X-rays not assessable by tuberculin skin tests can start concurrently with anti-TNF treatment. If the chemoprophylaxis regimen contains rifampicin, any maintenance dose of prednisolone should be doubled for

its duration, and note made of interaction with other immunosuppressive agents e.g. tacrolimus and ciclosporine treatment. (D)

It should be noted that no chemoprophylaxis regimen is wholly effective, protective efficacies being 60% for 6H²⁷ and 50% for 3RH²⁴. If patients who have had chemoprophylaxis develop symptoms suggestive of clinical TB they should be promptly and appropriately investigated. (D)

4.7 Management of clinical TB developing during anti-TNF-alpha treatment

If a patient develops active tuberculosis while on anti-TNF-alpha treatment, they should receive full antituberculosis chemotherapy¹⁵. (A) In these circumstances, which are different from TB disease diagnosed before anti-TNF-alpha treatment has started, the anti-TNF-alpha treatment can be continued if clinically indicated, because the patient would otherwise be prevented from receiving the continued clinical benefit to their underlying disease, and may have a flare up or major clinical deterioration (D). Although there are no good data in this area, it is known that HIV-positive individuals with reduced CD4 counts and clinical TB, who are

even more immunosuppressed than those on anti-TNF-alpha treatment, respond just as well to TB treatment as in those who are HIV-negative¹⁴.

Suggested Guidelines review date: Summer 2008

5. References, Tables and suggested Audit Criteria

5.1 References

1. Keane J, Gershon S, Wise RP, *et al*, Tuberculosis associated with infliximab, a tumor necrosis factor-alpha neutralizing agent. *N Engl J Med* 2001; **345**: 1098-104. (II)
2. Joint Committee on Vaccination and Immunisation. Tuberculin testing in Chapter 32: Vaccination and Immunisation. 1996. HMSO.
3. Mow WS, Abreu-Martin MT, Papadakis KA, Pitchon HE, Targan SR, Vasiliaukas EA. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. *Clin Gastroenterol Hepatol* 2004; **2**: 309-13.
4. Schuna AA, Megeff C. New drugs for the treatment of rheumatoid arthritis. *Am J Health Syst Pharm* 2000; **57**: 225-234.
5. Kornbluth A. Infliximab approved for use in Crohn's disease: a report on the FDAGI Advisory Committee Conference. *Inflamm Bowel Dis* 1998; **4**: 328-9.
6. Choy EHS, Punayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. *N Engl J Med* 2001; **344**: 907-16.
7. Weinblatt ME, Keystone EC, Furst DE, *et al*. Adalimumab, a fully human anti-tumour necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. *Arthritis Rheum* 2003; **48**: 855.
8. HUMIRA prescribing information: Issues December 2002, Abbott Laboratories, North Chicago, IL 600064, USA.
9. Gardam MA, Keystone EC, Menzies R, *et al*.. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. *The Lancet Inf Dis* 2003; **3**: 148-55.
10. Keane J, Gershon SK, Braun MM. Tuberculosis and treatment with infliximab.

N Engl J Med 2002; **346**; 625-6. (II)

11. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection with rheumatoid arthritis and the effect of infliximab therapy. *Arthritis Rheum* 2004; **50**: 372-379. (II)
12. Kumar D, Watson JM, Charlett A. *et al.* Tuberculosis in England and Wales in 1993; results of a national survey. *Thorax* 1997; **52**: 1060-7. (II)
13. Rose AMC, Watson JM, Graham C, Nunn AJ, Drobniowski F, Ormerod LP, *et al.* Tuberculosis at the end of the 20th Century in England and Wales: results of a national survey in 1998. *Thorax* 2001; **56**: 173-179. (II)
14. Pozniak A, Miller R, Ormerod LP. Treatment of tuberculosis in HIV-infected patients. *AIDS* 1999; **13**: 435-445.
15. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis: recommendations 1998. *Thorax* 1998; **53**: 536-545. (I).

18

16. International Union against Tuberculosis Committee on prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT Trial. *Bull of the World Health Organisation* 1982; **60**: 555-564. (I).
17. American Thoracic Society and Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. *Am J Resp Crit Care Med* 2000; **161**: S221-S247. (II)
18. Centers for Disease Control. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection – New York and Georgia, 2000. *Morb Mort Wkly Report* 2001; **50**: 289-91. (II)
19. Centers for Disease Control. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in the American Thoracic Society/CDC recommendations – United States 2001. *Morb Mort Wkly Report* 2001; **50**: 733-735. (II)
20. Joint Tuberculosis Committee of the British Thoracic Society. Control and prevention of tuberculosis: recommendations 2000. *Thorax* 2000; **55**: 887-901. (II)
21. Jasmer RM, Saukkonen JJ, Blumberg HM, *et al.* Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: A multicenter clinical trial. *Ann Intern Med* 2002; **137**: 640-47. (I)

22. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a seven year survey from a public health tuberculosis clinic. *JAMA* 1999; **281**: 1014-18. (II)
23. Bailey WC, Taylor SL, Dascomb HE, Greenberg HB, Ziskind MM. Disturbed hepatic function during isoniazid chemoprophylaxis. *Am Rev Resp Dis* 1973; **107**: 523-529. (II)
24. Hong Kong Chest Service, Tuberculosis Research Centre Madras, and British Medical Research Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. *Am Rev Resp Dis* 1992; **145**: 36-41. (I)
25. Lee AM, Mennone JZ, Jones RC, Paul WS. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. *Int J Tuberc Lung Dis* 2002; **6**: 995-1000. (II)
26. Stout JE, Engemann JJ, Cheng AC, Fortenberry ER, Hamilton CD. Safety of two months rifampin and pyrazinamide for treatment of latent tuberculosis. *AJRCCM Articles in Press*. Nov 21 2002: As doi:10.1164/rccm.200209-998OC. (II)
27. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons (Cochrane Review). In: *The Cochrane Library*, Issue 2, 2004. Chichester UK: John Wiley & Sons Ltd. (I)

5.2 Tables

TABLE 1 REVISED SIGN GRADING SYSTEM – GRADES OF RECOMMENDATION

- A At least one meta analysis, systematic review, or RCT rated as 1⁺⁺, and directly applicable to the target population; *or*
A systematic review of RCTs or a body of evidence consisting principally of studies rated as 1⁺, directly applicable to the target population, and demonstrating overall consistency of results.
- B A body of evidence including studies rated as 2⁺⁺, directly applicable to the target population, and demonstrating overall consistency of results; *or*
Extrapolated evidence from studies rated as 1⁺⁺ or 1⁺.
- C A body of evidence including studies rated as 2⁺, directly applicable to the target population and demonstrating overall consistency of results; *or*
Extrapolated evidence from studies rated as 2⁺.
- D Evidence level 3 or 4; *or*
Extrapolated evidence from studies rated as 2⁺.

TABLE 2 REVISED SIGN GRADING SYSTEM – LEVELS OF EVIDENCE

1 ⁺⁺	High quality meta-analyses, systematic reviews of randomized controlled trials (RCTs), or RCTs with a very low risk of bias.
1 ⁺	Well conducted meta analyses, systematic reviews of RCTs, or RCTs with a low risk of bias.
1-	Meta analyses, systematic reviews of RCTs or RCTs with a high risk of bias.
2 ⁺⁺	High quality systematic reviews of case-control or cohort or studies. High quality case-control or cohort studies with a very low risk of confounding, bias, or chance and a high probability that the relationship is causal.
2 ⁺	Well conducted case control or cohort studies with a very risk of confounding, bias, or chance and a moderate probability that the relationship is causal.
2 ⁻	Case control or cohort studies with a high risk of confounding, bias, or chance, and a significant risk that the relationship is not causal.
3	Non-analytical studies e.g. case reports, case series.
4	Expert opinion

TABLE 3 ANNUAL RISK OF TUBERCULOSIS DISEASE/100000 IN ENGLAND AND WALES

(A) Effect of Age (to the nearest whole number)

Age(years)	White	Black-African
0-14	1	47
15-34	2	314
35-54	4	168
55-74	7	204
>75	11	not available

(B) Effect of Place of birth/Duration of residence in England and Wales

Age	Place of birth	Years after first entry	All patient Rate	ISC* ethnic Rate
0-14	UK		3	21
	Abroad		31	88
15 and over	UK		4	59
15-34	Abroad	0-4	180	540
		5 years and over	53	87
35 and over	Abroad	0-4	146	593
		5 years and over	39	108

Population figures from the Office of National Statistics Labour Force Survey 2000
TB data from case reports to Enhanced TB Surveillance 2000 Health Protection Agency
*ISC= Indian Subcontinent

How to use (see also Table 4)

If white UK born use data from Table 1A

If Indian subcontinent (ISC) use Table 1B

If Black-African use Table 1A (similar data to Table 1B not yet available)

If either white non-UK born or other ethnic group use All patient rate Table 1B

If in doubt or in special circumstances consult local thoracic physician

TABLE 4 Sample Calculations based on Tables 3A and 3B

The weighted average risk for prophylaxis with isoniazid (6H) is 278/100000 which is used for these calculations. That for rifampicin/isoniazid (3RH) is higher at 1766/100000 but this regimen may need to be considered if a shorter duration of chemoprophylaxis is needed on clinical grounds (see 4.6)

Case Type	Annual risk of TBdisease/100000	TB risk adjusted x5 for anti-TNF effect	Risks of prophylaxis /100000 (Table 5)	Risk/benefit conclusion
White 55-74 UK born	7	35	278	Observation
Indian sub Continent >35 In UK 3 years	593	2965	278	Prophylaxis
Black-African 35-54	168	840	278	Prophylaxis
Other ethnic 35 or over In UK >5 years	39	195	278	Observation

TABLE 5 HEPATIC RISKS OF CHEMOPROPHYLAXIS

Reference	N=	Hepatitis/100000*	% Completion	Comments
<u>Regimen Isoniazid 6H</u>				
15	6965	480	78	65% protective efficacy (1 death from 6H)
21	282	1000	59	
22	11141	100	-	Female OR 3.3 (0.87-12.45) White OR 2.60 (0.75-8.95) Increase with age Chi ² 5.22
23	427	1170	-	
Weighted average	18815	278		
<u>Regimen Rifampicin/isoniazid 3RH</u>				
24	170	1766	-	50% protective efficacy in silicosis
<u>Regimen Rifampicin/pyrazinamide 2RZ</u>				
25	148	9459	57	Female OR 4.1 (1.2-14.3) Recent tuberculin conversion OR 14.3 (1.8-115)
21	307	7700	61	Age>35 OR 12.2 (1.49-100.3) OR 8.46 x isoniazid (1.9-76.5)
26	114	5300	67.5	
Weighted average	569	6648		
H=isoniazid R=Rifampicin Z=Pyrazinamide * Symptomatic or grade 3/4 hepatitis.				

5.3 Suggested Audit criteria

History of previous TB checked Y/N

Chest X-ray within 3 months of starting anti-TNF alpha treatment? Y/N

Chest X-ray normal? Y/N

If abnormal referred to TB specialist? Y/N

Tuberculin skin test possible pre-treatment? Y/N

If No – referred for risk stratification? Y/N

If skin test performed – positive? Y/N

If risk stratification performed – given treatment for latent TB infection? Y/N

Figure 1.

